Clinical

Dataset Information

0

Phase 2 Study of NX9 for Delineation of Bowel Anatomy


ABSTRACT: This study will evaluate marking and distention of the bowel of the oral contrast agent, NX9, at CT of the abdomen and pelvis, VLDCT with no contrast will be followed by VLDCT with NX9 contrast followed by CT with NX9 and standard IV contrast. Eligible subjects will have cancer or other GI disorders for which CT is typically used to assess their disease. This is an open label study with efficacy evaluated in a masked fashion following completion of the entire study. Results of the NX9 scans will not be used for treatment decisions. PK will be evaluated in a subset of subjects at a single center.

DISEASE(S): Gi Disorders,Gastrointestinal Diseases,Digestive System Diseases,Gi Carcinoma

PROVIDER: 2370031 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2018-07-06 | GSE113764 | GEO
2008-12-24 | GSE8164 | GEO
2016-03-16 | E-GEOD-74143 | biostudies-arrayexpress
2012-04-13 | E-GEOD-31235 | biostudies-arrayexpress
| PRJNA526873 | ENA
2013-05-30 | GSE47460 | GEO
2013-09-01 | GSE49428 | GEO
2013-09-01 | GSE49426 | GEO
| 2061960 | ecrin-mdr-crc
2015-06-11 | GSE69725 | GEO